[Clinical observation of flupentixol and melitracen combined with specific immunotherapy for treatment of allergic rhinitis patients with anxiety and depression].

• DOI: 10.13201/j.issn.1001-1781.2017.01.010
• Publication Date: 2017-01-01
• Authors: Zhihui Yi; Xiulin Yang; Junhua Ren; Wen Peng; Qiulin Liang
• Keywords: Depression

Objective:To explore the clinical effects of Flupentixol/Melitracencombined with specific immunotherapy in allergic rhinitis patients anxiety and depression. Method:Totally ninetynine moderate to severe persistent depression from October 2014 Sepetember 2015 were randomly divided into two groups: 45 experimental group (Flupentixol/Melitracen 10.5 mg，QD,treatment last 4 months)and 44 control group.All treated for 1 years. The nasal symptoms score, mini Rhinoconjunctivitis Quality life questionnaire(MiniRQLQ), Medication SAS SDS score curative effect observed before treatment, after months or one year treatment. drug reactions also recorded. Result:The VAS scores, MiniRQLQ medication scores groups who significantly reduced than that treatment.The differences statistically significant(P<0.05).Compared group, symptom decreased month treatment(P<0.05).After total effective rate was 84.4%, while 56.8%.After years excellence 57.8%, 22.7%.The significant(P<0.05). During course there thirteen cases mild adverse reactionsin (17.7%) group(11.4%). There no significant differences(P>0.05). Conclusion:Flupentixol melitracen combined could sifnificantlly relieve symptom, quality mental depression.is a safe reliable therapeutic regimen further improving symptoms,quality life,mental statusand efficacy anddepression.